Trelegy ellipta and Pregabalin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trelegy ellipta and Pregabalin. Common interactions include tinnitus among females and asthma among males.

The phase IV clinical study analyzes what interactions people who take Trelegy ellipta and Pregabalin have. It is created by eHealthMe based on reports of 70 people who take Trelegy ellipta and Pregabalin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

70 people who take Trelegy ellipta and Pregabalin together, and have interactions are studied.

What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 16,526 Trelegy ellipta users for its effectiveness, alternative drugs and more.

What is Pregabalin?

Pregabalin has active ingredients of pregabalin. It is often used in fibromyalgia. eHealthMe is studying from 53,090 Pregabalin users for its effectiveness, alternative drugs and more.

Number of Trelegy ellipta and Pregabalin reports submitted per year:

Common Trelegy Ellipta and Pregabalin drug interactions by gender *:

female:

Tinnitus
Uterine leiomyoma
Lower respiratory tract infection
Rash
Ataxia
Confusional state
Death
Micturition urgency
Oedema peripheral
Past-pointing

male:

Asthma
Hypertension
Bone density decreased
Cough
Depression
Emotional distress
Osteopenia
Respiratory failure
Alanine aminotransferase increased
Analgesic drug level decreased

Common Trelegy Ellipta and Pregabalin drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Asthma
Decreased activity

40-49:

Anaphylactic reaction
Bronchiectasis
Bursitis
Diverticulitis
Diverticulum intestinal
Hypersensitivity
Hyperthyroidism
Migraine
Polyp
Presbyacusis

50-59:

Somnolence
Rash
Asthma
Chest discomfort
Discomfort
Fall
Fatigue
Gastric disorder
Hospitalisation
Multiple fractures

60+:

Productive cough
Ataxia
Blister
Fatigue
Rash
Constipation
Cough
Fall
Haemoglobin decreased
Nausea

Common conditions people have *:

Psoriasis (immune-mediated disease that affects the skin): 12 people, 17.14%
Itching: 11 people, 15.71%
Dizziness: 11 people, 15.71%
Abdominal Distension: 11 people, 15.71%
Asthma: 8 people, 11.43%
Pain: 7 people, 10.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 5.71%
Bipolar Disorder (mood disorder): 4 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Trelegy ellipta and Pregabalin?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Bonnet U, Taazimi B, Grabbe HD, "Pregabalin-Related Hypertriglyceridemia", Psychosomatics, 2014 Nov .